PULSAR radiotherapy plus immunotherapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial combines a special type of radiation therapy (PULSAR) with immunotherapy (drugs that help your immune system fight cancer) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can better control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You have advanced liver cancer (hepatocellular carcinoma) that cannot be removed with surgery and has spread or is locally advanced.
- You are already receiving or are scheduled to receive immunotherapy (such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab).
- Your cancer must have at least one high-risk feature, like a tumor larger than 5 cm, tumor invasion into blood vessels or bile ducts, or spread outside the liver.
- You must have at least one measurable tumor that your doctor plans to treat with PULSAR.
- You should be in good overall condition (able to do daily activities) and have adequate liver function.
- You must not have had radiation to the same area before, and you cannot have certain serious health conditions or be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (PULSAR plus fecal microbiota transplant) for people with advanced liver cancer that stopped responding to initial therapy. It aims to see if this approach can help control the cancer again.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This study tests a combination of immunotherapy (iparomlimab and tuvonralimab) plus a targeted therapy (bevacizumab) with focused radiation to the tumor for people with liver cancer that cannot be removed surgically. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
This trial tests combining PULSAR (a type of radiation therapy) with immunotherapy drugs to treat gastric (stomach) cancer that cannot be surgically removed. You must have already completed at least 3 months of chemotherapy with immunotherapy and shown no cancer growth to qualify.
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.